Pathology, El Camino Hospital, Mountain View, CA, USA.
Pathology, Cleveland Clinic, Cleveland, OH, USA.
Histopathology. 2020 Nov;77(5):728-733. doi: 10.1111/his.14161. Epub 2020 Sep 27.
Invasive micropapillary carcinoma is a recognised aggressive urothelial carcinoma variant. One prior study focusing on non-invasive (pTa) high-grade papillary urothelial carcinoma with micropapillary architecture has been reported.
We collected bladder transurethral resection specimens showing non-invasive high-grade papillary urothelial carcinoma with non-hierarchical secondary papillae lacking fibrovascular cores (i.e. micropapillary architecture). Cases with any invasive component or any prior history of invasive urothelial carcinoma were excluded. Twenty cases were identified from 16 male and two female patients (aged 55-86 years). Micropapillary architecture comprised from 10 to 95% (mean = 31%), but non-invasive cribriform (15 cases, comprising 5-60%, mean = 19%) and villoglandular patterns (nine cases, comprising 5-60%, mean = 24%) were commonly admixed. Treatment data were available for 16 patients: surveillance (n = 13), cystoprostatectomy (n = 1), BCG plus mitomycin (n = 1) and BCG (n = 1). Follow-up data were available from 16 patients (range = 1-128 months, mean = 50 months): 13 patients had no new occurrences to date (81%), two had stage progression to pT1 papillary urothelial carcinoma (13%) with one dying of other causes, and one died of other causes with no evidence of disease (6%).
Non-invasive urothelial carcinomas with micropapillary architecture are often admixed with non-invasive cribriform and villoglandular patterns. Stage progression to lamina propria invasion in only two of 16 patients (13%) is not higher than expected for otherwise typical pTa high-grade urothelial carcinomas and no progression to invasive micropapillary carcinoma was identified, adding further support to the current World Health Organisation recommendation excluding use of the term 'micropapillary' for pTa urothelial carcinoma.
浸润性微乳头状癌是一种公认的侵袭性尿路上皮癌变体。此前有一项研究聚焦于非浸润性(pTa)高级别乳头状尿路上皮癌伴微乳头状结构。
我们收集了表现为非浸润性高级别乳头状尿路上皮癌伴非分层二级乳头、缺乏纤维血管核心(即微乳头状结构)的经尿道膀胱肿瘤切除术标本。排除有任何浸润性成分或任何先前浸润性尿路上皮癌病史的病例。从 16 名男性和 2 名女性患者(年龄 55-86 岁)中确定了 20 例。微乳头状结构占 10-95%(平均值=31%),但非浸润性筛状(15 例,占 5-60%,平均值=19%)和绒毛状腺体模式(9 例,占 5-60%,平均值=24%)通常混合存在。16 例患者的治疗数据可用:观察(n=13)、膀胱前列腺切除术(n=1)、BCG 加丝裂霉素(n=1)和 BCG(n=1)。16 例患者的随访数据可用(范围=1-128 个月,平均值=50 个月):13 例患者迄今为止无新发疾病(81%),2 例进展为 pT1 乳头状尿路上皮癌(13%),其中 1 例因其他原因死亡,1 例因其他原因死亡且无疾病证据(6%)。
伴微乳头状结构的非浸润性尿路上皮癌常与非浸润性筛状和绒毛状腺体模式混合存在。在 16 例患者中,仅有 2 例(13%)进展为固有层浸润,这并不高于其他典型 pTa 高级别尿路上皮癌的预期进展率,也未发现进展为浸润性微乳头状癌,这进一步支持当前世界卫生组织建议不为 pTa 尿路上皮癌使用“微乳头状”这一术语。